BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8332235)

  • 1. [Current therapy of multiple sclerosis. Oral tolerance induction to myelin antigens].
    Voltz R; Hohlfeld R
    Nervenarzt; 1993 Jun; 64(6):411-2. PubMed ID: 8332235
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple sclerosis. Presenting an odd autoantigen.
    Steinman L
    Nature; 1995 Jun; 375(6534):739-40. PubMed ID: 7541112
    [No Abstract]   [Full Text] [Related]  

  • 3. [Current therapy of multiple sclerosis: "T-cell vaccination"].
    Zipp F; Hohlfeld R
    Nervenarzt; 1994 Jun; 65(6):424-5. PubMed ID: 8072598
    [No Abstract]   [Full Text] [Related]  

  • 4. Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures.
    Karussis D; Slavin S
    J Neurol Sci; 2004 Aug; 223(1):59-64. PubMed ID: 15261562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen-Specific Treatment Modalities in MS: The Past, the Present, and the Future.
    Derdelinckx J; Cras P; Berneman ZN; Cools N
    Front Immunol; 2021; 12():624685. PubMed ID: 33679769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen-specific therapies in multiple sclerosis.
    van Noort JM
    Biotherapy; 1998; 10(3):237-50. PubMed ID: 9559979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigen-specific therapies in MS - Current concepts and novel approaches.
    Lutterotti A; Sospedra M; Martin R
    J Neurol Sci; 2008 Nov; 274(1-2):18-22. PubMed ID: 18599087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New therapies for multiple sclerosis--when?
    Waisbren BA
    Wis Med J; 1993 Aug; 92(8):448-50. PubMed ID: 8237027
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune response to myelin basic protein in multiple sclerosis.
    Hughes RA; Gray I; Clifford-Jones R; Stern M
    Proc R Soc Med; 1977 Dec; 70(12):874-6. PubMed ID: 601066
    [No Abstract]   [Full Text] [Related]  

  • 10. [Current findings on the pathogenesis of multiple sclerosis].
    Steck A
    Krankenpfl Soins Infirm; 1981 Jul; (7):57. PubMed ID: 6265695
    [No Abstract]   [Full Text] [Related]  

  • 11. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.
    Fontoura P; Garren H; Steinman L
    Int Rev Immunol; 2005; 24(5-6):415-46. PubMed ID: 16318989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis: classification revisited reveals homogeneity and recapitulation.
    Raine CS
    Ann Neurol; 2008 Jan; 63(1):1-3. PubMed ID: 18232014
    [No Abstract]   [Full Text] [Related]  

  • 13. [Apoptosis in multiple sclerosis. Etiopathogenetic relevance and prospects for new therapeutic strategies].
    Aktas O; Wendling U; Zschenderlein R; Zipp F
    Nervenarzt; 2000 Oct; 71(10):767-73. PubMed ID: 11082807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimyelin basic protein antibodies and cellular hypersensitivity in multiple sclerosis.
    Sheremata W; Wood DD; Moscarello MA
    Trans Am Neurol Assoc; 1976; 101():291-4. PubMed ID: 1028264
    [No Abstract]   [Full Text] [Related]  

  • 15. [Copolymer 1 in therapy of multiple sclerosis].
    Weilbach FX; Voltz R; Hohlfeld R; Hartung HP
    Nervenarzt; 1995 Jun; 66(6):473-7. PubMed ID: 7543660
    [No Abstract]   [Full Text] [Related]  

  • 16. [Perspectives in multiple sclerosis research].
    Lassmann H
    Wien Med Wochenschr; 1996; 146(19-20):528-32. PubMed ID: 9082653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen-specific therapies in multiple sclerosis.
    Sospedra M; Martin R
    Int Rev Immunol; 2005; 24(5-6):393-413. PubMed ID: 16318988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell vaccination in multiple sclerosis: immunoregulatory mechanism and prospects for therapy.
    Zhang J
    Crit Rev Immunol; 2001; 21(1-3):41-55. PubMed ID: 11642613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis.
    Sun W; Popat U; Hutton G; Zang YC; Krance R; Carrum G; Land GA; Heslop H; Brenner M; Zhang JZ
    Brain; 2004 May; 127(Pt 5):996-1008. PubMed ID: 14985264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
    Bar-Or A; Vollmer T; Antel J; Arnold DL; Bodner CA; Campagnolo D; Gianettoni J; Jalili F; Kachuck N; Lapierre Y; Niino M; Oger J; Price M; Rhodes S; Robinson WH; Shi FD; Utz PJ; Valone F; Weiner L; Steinman L; Garren H
    Arch Neurol; 2007 Oct; 64(10):1407-15. PubMed ID: 17698695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.